跳至主要内容
临床试验/ISRCTN10001405
ISRCTN10001405进行中(未招募)未知

Prospective Evaluation of AI R&D tool for patient stratification - Trial for Renal immuno-oncology model Experimental Evaluation (PEAR-TREE)

Ourotech Limited (trading as Pear Bio)0 个研究点目标入组 20 人开始时间: 2022年10月14日最近更新:
适应症

试验速览

阶段
未知
状态
进行中(未招募)
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

性别
All

入选标准

  • 1. Aged 18 years old and over
  • 2. Patients with operable kidney cancer
  • 3. Able to give informed consent
  • 4. Able to give 40 ml of blood and surgical sample yields >= 0.4 g of cancerous tissue

排除标准

  • 1. Inoperable or metastatic kidney cancer
  • 2. Pre-operative haemoglobin levels below 120g/l
  • 3. Patients who have already commenced chemotherapy, targeted therapy, immunotherapy or radiotherapy
  • 4. Recurrence of cancer from any other site than the kidney
  • 5. Any other disease or finding that renders the patient at high risk of treatment complications or interferes with obtaining informed consent

研究者

发起方
Ourotech Limited (trading as Pear Bio)

相似试验

nderstanding the usefulness of the PEAR-BIO platform... | 临床试验